SEC Form 8-K Summary
Business Context and Reporting Period
EUDA Health Holdings Limited filed this Current Report on April 10, 2023, regarding a Nasdaq delinquency notification received April 5, 2023. The issue relates to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. The Company stated that its financial statements and audit for the 2022 Form 10-K were not yet complete.
Material Changes Versus the Prior Comparable Period
The material development is the Company’s failure to timely file its 2022 Form 10-K, resulting in non-compliance with Nasdaq Listing Rule 5250(c)(1). The filing does not quantify any year-over-year financial changes.
Guidance, Outlook, Risks, and Unusual Items
- Nasdaq granted the Company 60 calendar days to submit a plan to regain compliance.
- If Nasdaq accepts the plan, it may grant up to 180 additional calendar days from the prescribed Form 10-K due date to regain compliance.
- If Nasdaq rejects the plan, the Company may appeal to a Nasdaq Hearings Panel.
- Management said a substantial portion of the required Form 10-K information had been completed but that additional time was needed to prepare, review, and finalize the financial statements; the auditors had not completed their audit.
- The notice had no immediate effect on the listing. The Company’s ordinary shares continued trading on Nasdaq under “EUDA.”
- Failure to complete the filing or regain compliance could create continued listing and trading risks. The filing also includes customary forward-looking statement risks and uncertainties.
Important Facts for Investors to Verify
- Whether the Company submitted its compliance plan within the required 60-day period.
- Whether Nasdaq accepted the plan and granted additional time.
- The actual filing date and contents of the fiscal 2022 Form 10-K.
- Whether the audit identified material adjustments, control issues, going-concern uncertainties, or other qualifications.
- Whether Nasdaq subsequently issued additional deficiency, suspension, delisting, or hearing notices.